Lajos Géczi
A5101750453- Testicular diseases and treatments
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Urinary and Genital Oncology Studies
- Cancer, Lipids, and Metabolism
- Sarcoma Diagnosis and Treatment
- Sexual Differentiation and Disorders
- Renal and related cancers
- Cancer Genomics and Diagnostics
- Hormonal and reproductive studies
- Cancer Treatment and Pharmacology
- Multiple Myeloma Research and Treatments
- Ovarian cancer diagnosis and treatment
- Hearing, Cochlea, Tinnitus, Genetics
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Pancreatic and Hepatic Oncology Research
- Economic and Financial Impacts of Cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Urologic and reproductive health conditions
- Sperm and Testicular Function
- Neuroblastoma Research and Treatments
- Lung Cancer Treatments and Mutations
National Institute of Oncology
2015-2024
Országos Pszichiátriai és Neurológiai Intézet
2013-2021
National Institute of Criminology
2021
Ministry of Human Capacities
2019
Institut Claudius Regaud
2017
Sidney Kimmel Comprehensive Cancer Center
2017
Canadian Urological Association
2016
AstraZeneca (Brazil)
2016
Laboratoire d'études sur les monothéismes
2016
Semmelweis University
2007
Previous studies suggested that serum levels of microRNA (miR)-371a-3p (so-called M371 test) have a much higher sensitivity and specificity than the classic markers testicular germ cell tumors (GCTs) are applicable toward both seminoma nonseminoma. We sought to confirm usefulness this test as novel biomarker for GCT.
Purpose Cabazitaxel 25 mg/m2 (C25) significantly improved overall survival (OS) versus mitoxantrone ( P < .001) in postdocetaxel patients with metastatic castration-resistant prostate cancer (mCRPC) the phase III TROPIC study. The PROSELICA study ClinicalTrials.gov identifier: NCT01308580) assessed noninferiority of cabazitaxel 20 (C20) C25 mCRPC. Methods Patients were stratified by Eastern Cooperative Oncology Group performance status, measurability disease per Response Evaluation Criteria...
Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in broader, pretreated population, including patients ineligible the pivotal IMvigor211 phase 3 trial of atezolizumab. To determine safety and efficacy an international real-world setting. Between November 2016 March 2018 (median follow-up 12.7 mo), 1004 with advanced or metastatic nonurothelial urinary tract carcinoma who experienced...
A family history of disease is a strong risk factor for testicular germ cell tumour (TGCT). In order to identify the location putative TGCT susceptibility gene(s) we conducted linkage search in 237 pedigrees with two or more cases TGCT. One hundred and seventy-nine were evaluated genome-wide an average inter-marker distance 10 cM. An additional 58 used intensively investigate several genomic regions interest. Genetic analysis was performed ALLEGRO software using model-based parametric...
The limited data on cancer phenotypes in men with germline BRCA1 and BRCA2 pathogenic variants (PVs) have hampered the development of evidence-based recommendations for early detection risk reduction this population.
Somatic mutations of the KIT gene have been reported in mast cell diseases and gastrointestinal stromal tumours. Recently, they also found mediastinal testicular germ tumours (TGCTs), particularly cases with bilateral disease. We screened coding sequence (except exon 1) for germline 240 pedigrees two or more TGCT. No were found. Exons 10, 11 17 examined somatic 123 TGCT from 93 multiple-case cancer families. Five identified; four missense amino-acid substitutions one was a 12 bp in-frame...
Abiraterone acetate is combined with prednisone, 5 mg, twice daily for metastatic castration-resistant prostate cancer (mCRPC) and once newly diagnosed, high-risk, castration-sensitive cancer. Understanding the physiological effects of these other regimens important.To evaluate safety abiraterone 4 glucocorticoid regimens.Open-label, randomized clinical trial (1:1:1:1) 164 men mCRPC from 22 hospitals in countries who were randomly assigned to 1 intervention groups between June 2013 October...
Abstract Pathogenic sequence variants (PSV) in BRCA1 or BRCA2 (BRCA1/2) are associated with increased risk and severity of prostate cancer. We evaluated whether PSVs BRCA1/2 were overall cancer high grade (Gleason 8+) using an international sample 65 171 male PSV carriers cancer, 3,388 2,880 without the 3′ region (c.7914+) significantly elevated compared reference bin c.1001-c.7913 [HR = 1.78; 95% confidence interval (CI), 1.25–2.52; P 0.001], as well Gleason 8+ (HR 3.11; CI, 1.63–5.95;...
TPS4590 Background: Only 5%-15% of patients (pts) with advanced bladder cancer attain long-term survival standard first-line cisplatin-based chemotherapy. Programmed death 1 (PD-1)/PD-L1 inhibitors have proven effective in recurrent, urothelial cancer. Emerging data suggest these agents may also be useful the setting. In KEYNOTE-052, pembro, an anti–PD-1 antibody, demonstrated antitumor activity and acceptable safety cisplatin-ineligible pts KEYNOTE-361 (NCT02853305) is a randomized,...
5008 Background: The Phase III TROPIC study (NCT00417079) reported a significant improvement in overall survival (OS) for C plus prednisone (P) (25 mg/m2once every 3 weeks 10 mg orally once daily) versus mitoxantrone P (Hazard Ratio [HR] 0.70; < 0.0001) pts with mCRPC previously treated D. This PROSELICA (NCT01308580) was designed to determine the relative efficacy and safety profile of C20 compared C25 P. Methods: In this randomized, open-label, multinational phase study, ECOG performance...
The characteristics and risk factors of the long-term ototoxic effect cisplatin in testicular cancer patients was studied by measuring distortion product otoacoustic emissions (DPOAEs), which is a highly sensitive, new method for detecting high-frequency hearing loss.223 with median follow-up time 4.27 years (range 0.5-20 years) age 37 18-55 were assessed DPOAE. 100 mg/m2 administered per cycle, EP, BEP, VeIP, VIP or VPB regimens. control group consisted 40 without chemotherapy (median 35...
Abstract A base substitution in the mouse Dnd1 gene resulting a truncated Dnd protein has been shown to be responsible for germ cell loss and development of testicular tumors (TGCT) 129 strain mice. We investigated human orthologue this 263 patients (165 with family history TGCT 98 without) found rare heterozygous variant, p. Glu86Ala, single case. This variant was not present control chromosomes (0/4,132). Analysis an additional 842 index cases (269 573 did reveal any instances. The is...